Written answers
Tuesday, 17 May 2022
Department of Health
Medicinal Products
Neasa Hourigan (Dublin Central, Green Party)
Link to this: Individually | In context | Oireachtas source
650. To ask the Minister for Health his plans to make Kaftrio available to children with cystic fibrosis who have only one delta F508 mutation and as such have no other suitable modulator; and if he will make a statement on the matter. [24167/22]
Gary Gannon (Dublin Central, Social Democrats)
Link to this: Individually | In context | Oireachtas source
683. To ask the Minister for Health if his attention has been drawn to the situation of 35 children with cystic fibrosis (details supplied) who are being denied access to the life-changing drug kaftrio; and if he will make a statement on the matter. [24368/22]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
I propose to take Questions Nos. 650 and 683 together.
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
No comments